|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM363676864 |
| 003 |
DE-627 |
| 005 |
20231226093847.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202304982
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1212.xml
|
| 035 |
|
|
|a (DE-627)NLM363676864
|
| 035 |
|
|
|a (NLM)37875431
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xiao, Leyi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Microenvironment-Regulating Drug Delivery Nanoparticles for Treating and Preventing Typical Biofilm-Induced Oral Diseases
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 24.10.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The oral cavity comprises an environment full of microorganisms. Dysregulation of this microbial-cellular microenvironment will lead to a series of oral diseases, such as implant-associated infection caused by Staphylococcus aureus (S. aureus) biofilms and periodontitis initiated by Streptococcus oralis (S. oralis). In this study, a liposome-encapsulated indocyanine green (ICG) and rapamycin drug-delivery nanoparticle (ICG-rapamycin) is designed to treat and prevent two typical biofilm-induced oral diseases by regulating the microbial-cellular microenvironment. ICG-rapamycin elevates the reactive oxygen species (ROS) and temperature levels to facilitate photodynamic and photothermal mechanisms under near-infrared (NIR) laser irradiation for anti-bacteria. In addition, it prevents biofilm formation by promoting bacterial motility with increasing the ATP levels. The nanoparticles modulate the microbial-cellular interaction to reduce cellular inflammation and enhance bacterial clearance, which includes promoting the M2 polarization of macrophages, upregulating the anti-inflammatory factor TGF-β, and enhancing the bacterial phagocytosis of macrophages. Based on these findings, ICG-rapamycin is applied to implant-infected and periodontitis animal models to confirm the effects in vivo. This study demonstrates that ICG-rapamycin can treat and prevent biofilm-induced oral diseases by regulating the microbial-cellular microenvironment, thus providing a promising strategy for future clinical applications
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a bacteria-host microenvironment
|
| 650 |
|
4 |
|a implant-associated infection
|
| 650 |
|
4 |
|a oral-disease therapy
|
| 650 |
|
4 |
|a periodontitis
|
| 650 |
|
4 |
|a photodynamic-photothermal therapy
|
| 700 |
1 |
|
|a Feng, Mengge
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Chen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiao, Qi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cui, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Yufeng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2023) vom: 24. Okt., Seite e2304982
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g year:2023
|g day:24
|g month:10
|g pages:e2304982
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202304982
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 24
|c 10
|h e2304982
|